109 related articles for article (PubMed ID: 12631604)
21. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
[TBL] [Abstract][Full Text] [Related]
24. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
[TBL] [Abstract][Full Text] [Related]
26. [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].
Zhang J; Zhang JH; Liu Y; Hao XM; Fang ZX; Li SL
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3268-71. PubMed ID: 18396622
[TBL] [Abstract][Full Text] [Related]
27. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
28. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
Matsubara J; Yamada Y; Hirashima Y; Takahari D; Okita NT; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
Clin Cancer Res; 2008 May; 14(10):3022-9. PubMed ID: 18483367
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01.
Sacco M; Valentini M; Belfiglio M; Pellegrini F; De Berardis G; Franciosi M; Nicolucci A;
J Clin Oncol; 2003 Jun; 21(12):2276-81. PubMed ID: 12805326
[TBL] [Abstract][Full Text] [Related]
30. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.
Faneyte IF; Peterse JL; Van Tinteren H; Pronk C; Bontenbal M; Beex LV; van der Wall E; Richel DJ; Nooij MA; Voest EE; Hupperets P; Ten Vergert EM; de Vries EG; Rodenhuis S; van de Vijver MJ
Clin Cancer Res; 2004 Jul; 10(13):4457-63. PubMed ID: 15240537
[TBL] [Abstract][Full Text] [Related]
31. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
32. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
[TBL] [Abstract][Full Text] [Related]
33. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
34. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
[TBL] [Abstract][Full Text] [Related]
35. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
36. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
Pierce LJ; Hutchins LF; Green SR; Lew DL; Gralow JR; Livingston RB; Osborne CK; Albain KS
J Clin Oncol; 2005 Jan; 23(1):24-9. PubMed ID: 15545669
[TBL] [Abstract][Full Text] [Related]
37. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
38. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
39. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Johansen J; Overgaard J; Overgaard M
Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
[TBL] [Abstract][Full Text] [Related]
40. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]